IRadimed stock
IRMDNASDAQIRadimed Corporation, HealthcareISIN US46266A1097
75Score 75 out of 100, Strong
Price and trend
49 / 100
Price history
−1.4% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.2% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 19% below its 52-week high. Largest decline in 12 years: 76% (November 2015 to April 2017).
Chart figures for advanced users
- SMA 50$85.32
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$91.81
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$76.68
- The lowest closing price of the last twelve months.
- Resistance$105.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- IRadimed Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $1.09B, is number 56 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $83.81M (up 14.4% year on year) and earnings of $22.48M (up 16.9%).
- MEQIRI Score 75 out of 100 (Strong): rank 69 of 702 in Healthcare, median 53.
Show more
- The P/E is 45.8 (Medical (Devices) median 29.1, own median of recent years 35.5).
- Our model puts fair value at $61.08, with the price 40% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 74.3% a year since 2020.Growth 99
- High return on capitalReturn on invested capital 53% in fiscal 2025, Medical (Devices) median 5.4%.Profitability 95
- Growing faster than its industryRevenue up 21.5% a year since 2020, Medical (Devices) median 13.8%.Growth 99
Weaknesses
- Richly valuedP/E 45.8, Medical (Devices) median 29.1, own median 35.5.Valuation 22
Its standout strengths are growth and fundamentals, while momentum and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 77 to 75.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $46.98 and expensive above $87.25 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $68.03 (cash-flow model) and $54.13 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $54.95, at 7.8% it would be $70.30.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11% on the twelve months before. Revenue has grown strongly since 2012, at around 20% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating 31%, net 27%.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 9 Feb 2027in 88 days
- Last reported
- 30 Oct 2026EPS reported $0.55 (expected $0.55)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.10−0.8%
- Revenue
- $92.2M+0.1%
- Earnings per share
- $2.44−0.7%
- Revenue
- $102.33M−1.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.8%2026 guidance reaffirmed: revenue of $91 million to $96 million, non-GAAP EPS of $2.09 to $2.24; third quarter revenue of $23 million to $24.5 million expected.
The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.98M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Allen Monty KSale
3 Sept 2026, Board
- Shares
- 1,419
- Price
- $86.41
- Value
- $122,622
- Scharen-Guivel Hilda FrederiqueSale
4 Jun 2026, Board
- Shares
- 3,000
- Price
- $95.00
- Value
- $285,000
- Susi Roger E.Sale
1 Jun 2026, 10 percent owner, officer: CEO, President, Chairman
- Shares
- 2,500
- Price
- $90.60
- Value
- $226,507
Show 4 more
- Susi Roger E.Sale
27 May 2026, 10 percent owner, officer: CEO, President, Chairman
- Shares
- 2,500
- Price
- $91.95
- Value
- $229,878
- Susi Roger E.Sale
26 May 2026, 10 percent owner, officer: CEO, President, Chairman
- Shares
- 5,000
- Price
- $92.23
- Value
- $461,166
- Susi Roger E.Sale
19 May 2026, 10 percent owner, officer: CEO, President, Chairman
- Shares
- 2,500
- Price
- $87.88
- Value
- $219,694
- Susi Roger E.Sale
18 May 2026, 10 percent owner, officer: CEO, President, Chairman
- Shares
- 5,000
- Price
- $87.51
- Value
- $437,571
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at IRadimed
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- PROCEPT BioRoboticsPRCT $1.35B41
- Tandem Diabetes CareTNDM $1.22B43
- Integra LifeSciences HoldingsIART $1.12B48
- Alphatec HoldingsATEC $1.1B34
- SI-BONESIBN $1.09B47
- AdaptHealthAHCO $1.07B32
- CeriBellCBLL $1.02B49
- ArtivionAORT $946.52M32
ETFs that hold IRadimed
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Show 4 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.